GlassScriptPhysician profile
Daman Singh
NPI 1659821601
$3,124.45
in general payments reported to CMS, 2019-2025
19 companies · $190 in 2025
The $190 reported for 2025 was more than what 75% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.94 · 2020: $387 · 2021: $583 · 2022: $389 · 2023: $650 · 2024: $913 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $869.67 | 2020-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $661.82 | 2020-2025 | Eliquis, Camzyos |
| Alexion Pharmaceuticals, INC. | $311.93 | 2021-2024 | Soliris, Ultomiris |
| Abbvie INC. | $206.94 | 2023-2025 | Dalvance, Teflaro, Avycaz |
| Pfizer INC. | $158.10 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $154.18 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $136.15 | 2024 | Giapreza, Xerava |
| Merck Sharp & Dohme LLC | $134.93 | 2024-2025 | Zerbaxa, Dificid, Prevymis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.89 | 2023-2024 | Jardiance |
| Aimmune Therapeutics, INC. | $107.05 | 2023-2025 | Vowst |
| Shionogi INC | $58.30 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $46.84 | 2019-2021 | |
| Tetraphase Pharmaceuticals, INC. | $45.37 | 2025 | |
| Ceribell, INC. | $24.53 | 2025 | Pocket Eeg Device |
| Genzyme Corporation | $21.83 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.31 | 2021 | |
| Tactile Systems Technology INC | $18.74 | 2023 | Flexitouch Plus, Entre Plus |
| Gilead Sciences, INC. | $16.01 | 2023 | Veklury |
| Vapotherm INC | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daman Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.